Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 102 entries
Sorted by: Best Match Show Resources per page
Bipolar Disorder and Parkinson's Disease: A .

Frontiers in neurology

Erro R, Landolfi A, D'Agostino G, Pace L, Picillo M, Scarano M, Cuocolo A, Pappatá S, Vitale C, Pellecchia MT, Monteleone P, Barone P.
PMID: 33927683
Front Neurol. 2021 Apr 13;12:652375. doi: 10.3389/fneur.2021.652375. eCollection 2021.

No abstract available.

Cite
Erro R, Landolfi A, D'Agostino G, et al. Bipolar Disorder and Parkinson's Disease: A . Front Neurol. 2021;12:652375doi: 10.3389/fneur.2021.652375.
Erro, R., Landolfi, A., D'Agostino, G., Pace, L., Picillo, M., Scarano, M., Cuocolo, A., Pappatá, S., Vitale, C., Pellecchia, M. T., Monteleone, P., & Barone, P. (2021). Bipolar Disorder and Parkinson's Disease: A . Frontiers in neurology, 12652375. https://doi.org/10.3389/fneur.2021.652375
Erro, Roberto, et al. "Bipolar Disorder and Parkinson's Disease: A ." Frontiers in neurology vol. 12 (2021): 652375. doi: https://doi.org/10.3389/fneur.2021.652375
Erro R, Landolfi A, D'Agostino G, Pace L, Picillo M, Scarano M, Cuocolo A, Pappatá S, Vitale C, Pellecchia MT, Monteleone P, Barone P. Bipolar Disorder and Parkinson's Disease: A . Front Neurol. 2021 Apr 13;12:652375. doi: 10.3389/fneur.2021.652375. eCollection 2021. PMID: 33927683; PMCID: PMC8076537.
Copy Download .nbib Format: NLM
Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials.

Journal of the National Cancer Institute

Efficace F, Cella D, Aaronson NK, Calvert M, Cottone F, Di Maio M, Perrone F, Sparano F, Gamper EM, Vignetti M, Giesinger JM.
PMID: 34508610
J Natl Cancer Inst. 2021 Sep 11; doi: 10.1093/jnci/djab177. Epub 2021 Sep 11.

Some concerns have been raised about potential bias in patient-reported outcome (PRO) results from open-label cancer randomized controlled trials (RCTs). We investigated if open-label trials favor the experimental treatment over the standard treatment more frequently than blinded trials. We...

Cite
Efficace F, Cella D, Aaronson NK, et al. Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. J Natl Cancer Inst. 2021;doi: 10.1093/jnci/djab177.
Efficace, F., Cella, D., Aaronson, N. K., Calvert, M., Cottone, F., Di Maio, M., Perrone, F., Sparano, F., Gamper, E. M., Vignetti, M., & Giesinger, J. M. (2021). Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. Journal of the National Cancer Institute, . https://doi.org/10.1093/jnci/djab177
Efficace, Fabio, et al. "Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials." Journal of the National Cancer Institute vol. (2021). doi: https://doi.org/10.1093/jnci/djab177
Efficace F, Cella D, Aaronson NK, Calvert M, Cottone F, Di Maio M, Perrone F, Sparano F, Gamper EM, Vignetti M, Giesinger JM. Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. J Natl Cancer Inst. 2021 Sep 11; doi: 10.1093/jnci/djab177. Epub 2021 Sep 11. PMID: 34508610.
Copy Download .nbib Format: NLM
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.

JNCI cancer spectrum

Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF.
PMID: 32337478
JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz049. doi: 10.1093/jncics/pkz049. eCollection 2019 Dec.

Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened in Toronto, Canada, in February 2018 to review the...

Cite
Dowling RJO, Sparano JA, Goodwin PJ, et al. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019;3(4):pkz049doi: 10.1093/jncics/pkz049.
Dowling, R. J. O., Sparano, J. A., Goodwin, P. J., Bidard, F. C., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., Meric-Bernstam, F., Perlmutter, J., Sledge, G. W., Thorat, M. A., Bratman, S. V., Carey, L. A., Chang, M. C., DeMichele, A., Ennis, M., Jerzak, K. J., Korde, L. A., Lohmann, A. E., Mamounas, E. P., Parulekar, W. R., Regan, M. M., Schramek, D., Stambolic, V., Whelan, T. J., Wolff, A. C., Woodgett, J. R., Kalinsky, K., & Hayes, D. F. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI cancer spectrum, 3(4), pkz049. https://doi.org/10.1093/jncics/pkz049
Dowling, Ryan J O, et al. "Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions." JNCI cancer spectrum vol. 3,4 (2019): pkz049. doi: https://doi.org/10.1093/jncics/pkz049
Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz049. doi: 10.1093/jncics/pkz049. eCollection 2019 Dec. PMID: 32337478; PMCID: PMC7050024.
Copy Download .nbib Format: NLM
Reply to T. Shimoi et al and Y. Shimanuki et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD.
PMID: 34554848
J Clin Oncol. 2021 Nov 01;39(31):3522-3524. doi: 10.1200/JCO.21.01905. Epub 2021 Sep 23.

No abstract available.

Cite
Mayer IA, Zhao F, Arteaga CL, et al. Reply to T. Shimoi et al and Y. Shimanuki et al. J Clin Oncol. 2021;39(31):3522-3524doi: 10.1200/JCO.21.01905.
Mayer, I. A., Zhao, F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., Tevaarwerk, A. J., Garcia, S. F., Smith, K. L., Makower, D. F., Block, M., Morley, K. A., Jani, C. R., Mescher, C., Dewani, S. J., Tawfik, B., Flaum, L. E., Mayer, E. L., Sikov, W. M., Rodler, E. T., Wagner, L. I., DeMichele, A. M., Sparano, J. A., Wolff, A. C., & Miller, K. D. (2021). Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(31), 3522-3524. https://doi.org/10.1200/JCO.21.01905
Mayer, Ingrid A, et al. "Reply to T. Shimoi et al and Y. Shimanuki et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,31 (2021): 3522-3524. doi: https://doi.org/10.1200/JCO.21.01905
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. J Clin Oncol. 2021 Nov 01;39(31):3522-3524. doi: 10.1200/JCO.21.01905. Epub 2021 Sep 23. PMID: 34554848; PMCID: PMC8547907.
Copy Download .nbib Format: NLM
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

NPJ breast cancer

Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.
PMID: 31602395
NPJ Breast Cancer. 2019 Oct 08;5:34. doi: 10.1038/s41523-019-0130-x. eCollection 2019.

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of...

Cite
Page DB, Bear H, Prabhakaran S, et al. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019;5:34doi: 10.1038/s41523-019-0130-x.
Page, D. B., Bear, H., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E., McArthur, H., Balko, J. M., Gameiro, S. R., Nanda, R., Gulley, J. L., Kalinsky, K., White, J., Litton, J., Chmura, S. J., Polley, M. Y., Vincent, B., Cescon, D. W., Disis, M. L., Sparano, J. A., Mittendorf, E. A., & Adams, S. (2019). Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ breast cancer, 534. https://doi.org/10.1038/s41523-019-0130-x
Page, David B, et al. "Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer." NPJ breast cancer vol. 5 (2019): 34. doi: https://doi.org/10.1038/s41523-019-0130-x
Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019 Oct 08;5:34. doi: 10.1038/s41523-019-0130-x. eCollection 2019. PMID: 31602395; PMCID: PMC6783471.
Copy Download .nbib Format: NLM
Correction to: Multiple spontaneous skull base cerebrospinal fluid leaks: some insights from an international retrospective collaborative study.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Dallan I, Cambi C, Emanuelli E, Cazzador D, Canevari FR, Borsetto D, Tysome JR, Donnelly NP, Rigante M, Georgalas C, Alobid I, Molteni G, Marchioni D, Shahzada AK, Scarano M, Seccia V, Pasquini E.
PMID: 32797274
Eur Arch Otorhinolaryngol. 2020 Dec;277(12):3365. doi: 10.1007/s00405-020-06283-2.

In the original publication of the article, the following affiliation "Medical school, University of Nicosia, Nicosia, Cyprus" of the author "Christos Georgalas" was missed and included in this correction.

Cite
Dallan I, Cambi C, Emanuelli E, et al. Correction to: Multiple spontaneous skull base cerebrospinal fluid leaks: some insights from an international retrospective collaborative study. Eur Arch Otorhinolaryngol. 2020;277(12):3365doi: 10.1007/s00405-020-06283-2.
Dallan, I., Cambi, C., Emanuelli, E., Cazzador, D., Canevari, F. R., Borsetto, D., Tysome, J. R., Donnelly, N. P., Rigante, M., Georgalas, C., Alobid, I., Molteni, G., Marchioni, D., Shahzada, A. K., Scarano, M., Seccia, V., & Pasquini, E. (2020). Correction to: Multiple spontaneous skull base cerebrospinal fluid leaks: some insights from an international retrospective collaborative study. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 277(12), 3365. https://doi.org/10.1007/s00405-020-06283-2
Dallan, Iacopo, et al. "Correction to: Multiple spontaneous skull base cerebrospinal fluid leaks: some insights from an international retrospective collaborative study." European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery vol. 277,12 (2020): 3365. doi: https://doi.org/10.1007/s00405-020-06283-2
Dallan I, Cambi C, Emanuelli E, Cazzador D, Canevari FR, Borsetto D, Tysome JR, Donnelly NP, Rigante M, Georgalas C, Alobid I, Molteni G, Marchioni D, Shahzada AK, Scarano M, Seccia V, Pasquini E. Correction to: Multiple spontaneous skull base cerebrospinal fluid leaks: some insights from an international retrospective collaborative study. Eur Arch Otorhinolaryngol. 2020 Dec;277(12):3365. doi: 10.1007/s00405-020-06283-2. PMID: 32797274.
Copy Download .nbib Format: NLM
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.

JNCI cancer spectrum

Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ.
PMID: 32337479
JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz050. doi: 10.1093/jncics/pkz050. eCollection 2019 Dec.

Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original diagnosis, and represent a major obstacle to the effective...

Cite
Dowling RJO, Kalinsky K, Hayes DF, et al. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019;3(4):pkz050doi: 10.1093/jncics/pkz050.
Dowling, R. J. O., Kalinsky, K., Hayes, D. F., Bidard, F. C., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., Meric-Bernstam, F., Perlmutter, J., Sledge, G. W., Bratman, S. V., Carey, L. A., Chang, M. C., DeMichele, A., Ennis, M., Jerzak, K. J., Korde, L. A., Lohmann, A. E., Mamounas, E. P., Parulekar, W. R., Regan, M. M., Schramek, D., Stambolic, V., Thorat, M. A., Whelan, T. J., Wolff, A. C., Woodgett, J. R., Sparano, J. A., & Goodwin, P. J. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI cancer spectrum, 3(4), pkz050. https://doi.org/10.1093/jncics/pkz050
Dowling, Ryan J O, et al. "Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations." JNCI cancer spectrum vol. 3,4 (2019): pkz050. doi: https://doi.org/10.1093/jncics/pkz050
Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz050. doi: 10.1093/jncics/pkz050. eCollection 2019 Dec. PMID: 32337479; PMCID: PMC7049988.
Copy Download .nbib Format: NLM
Learning from big data: are we undertreating older women with high-risk breast cancer?.

NPJ breast cancer

Sparano JA, Muss H.
PMID: 28721380
NPJ Breast Cancer. 2016 Jun 08;2:16019. doi: 10.1038/npjbcancer.2016.19. eCollection 2016.

No abstract available.

Cite
Sparano JA, Muss H. Learning from big data: are we undertreating older women with high-risk breast cancer?. NPJ Breast Cancer. 2016;2:16019doi: 10.1038/npjbcancer.2016.19.
Sparano, J. A., & Muss, H. (2016). Learning from big data: are we undertreating older women with high-risk breast cancer?. NPJ breast cancer, 216019. https://doi.org/10.1038/npjbcancer.2016.19
Sparano, Joseph A, and Muss, Hyman. "Learning from big data: are we undertreating older women with high-risk breast cancer?." NPJ breast cancer vol. 2 (2016): 16019. doi: https://doi.org/10.1038/npjbcancer.2016.19
Sparano JA, Muss H. Learning from big data: are we undertreating older women with high-risk breast cancer?. NPJ Breast Cancer. 2016 Jun 08;2:16019. doi: 10.1038/npjbcancer.2016.19. eCollection 2016. PMID: 28721380; PMCID: PMC5515332.
Copy Download .nbib Format: NLM
The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Oncotarget

Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE.
PMID: 29312549
Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12.

We previously identified the transcription factor ZNF217 (human) / Zfp217 (mouse) as an oncogene and prognostic indicator of reduced survival, increased metastasis, and reduced response to therapy in breast cancer patients. Here we investigated the role of Zfp217 in...

Cite
Suarez CD, Wu J, Badve SS, et al. The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget. 2017;8(65):108534-108547doi: 10.18632/oncotarget.19308.
Suarez, C. D., Wu, J., Badve, S. S., Sparano, J. A., Kaliney, W., & Littlepage, L. E. (2017). The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget, 8(65), 108534-108547. https://doi.org/10.18632/oncotarget.19308
Suarez, Christopher D, et al. "The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance." Oncotarget vol. 8,65 (2017): 108534-108547. doi: https://doi.org/10.18632/oncotarget.19308
Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE. The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12. PMID: 29312549; PMCID: PMC5752462.
Copy Download .nbib Format: NLM
Thrombophilia-Related Complications in the Treatment of a Left Atrial Appendage Thrombus: A Case Report.

Journal of cardiovascular echography

Parato VM, Scarano M, Labanti B.
PMID: 28465906
J Cardiovasc Echogr. 2014 Apr-Jun;24(2):64-65. doi: 10.4103/2211-4122.135621.

Trans-esophageal echocardiography (TEE) revealed a left atrial appendage (LAA) thrombus in an 84-year-old woman with nonvalvular atrial fibrillation not known before our evaluation. In her medical history, there were hypertension, dyslipidemia and a previous pulmonary embolism. She was taking...

Cite
Parato VM, Scarano M, Labanti B. Thrombophilia-Related Complications in the Treatment of a Left Atrial Appendage Thrombus: A Case Report. J Cardiovasc Echogr. 2014;24(2):64-65doi: 10.4103/2211-4122.135621.
Parato, V. M., Scarano, M., & Labanti, B. (2014). Thrombophilia-Related Complications in the Treatment of a Left Atrial Appendage Thrombus: A Case Report. Journal of cardiovascular echography, 24(2), 64-65. https://doi.org/10.4103/2211-4122.135621
Parato, Vito Maurizio, et al. "Thrombophilia-Related Complications in the Treatment of a Left Atrial Appendage Thrombus: A Case Report." Journal of cardiovascular echography vol. 24,2 (2014): 64-65. doi: https://doi.org/10.4103/2211-4122.135621
Parato VM, Scarano M, Labanti B. Thrombophilia-Related Complications in the Treatment of a Left Atrial Appendage Thrombus: A Case Report. J Cardiovasc Echogr. 2014 Apr-Jun;24(2):64-65. doi: 10.4103/2211-4122.135621. PMID: 28465906; PMCID: PMC5353425.
Copy Download .nbib Format: NLM
Stop-event-related potentials from intracranial electrodes reveal a key role of premotor and motor cortices in stopping ongoing movements.

Frontiers in neuroengineering

Mattia M, Spadacenta S, Pavone L, Quarato P, Esposito V, Sparano A, Sebastiano F, Di Gennaro G, Morace R, Cantore G, Mirabella G.
PMID: 22754525
Front Neuroeng. 2012 Jun 29;5:12. doi: 10.3389/fneng.2012.00012. eCollection 2012.

In humans, the ability to withhold manual motor responses seems to rely on a right-lateralized frontal-basal ganglia-thalamic network, including the pre-supplementary motor area and the inferior frontal gyrus (IFG). These areas should drive subthalamic nuclei to implement movement inhibition...

Cite
Mattia M, Spadacenta S, Pavone L, et al. Stop-event-related potentials from intracranial electrodes reveal a key role of premotor and motor cortices in stopping ongoing movements. Front Neuroeng. 2012;5:12doi: 10.3389/fneng.2012.00012.
Mattia, M., Spadacenta, S., Pavone, L., Quarato, P., Esposito, V., Sparano, A., Sebastiano, F., Di Gennaro, G., Morace, R., Cantore, G., & Mirabella, G. (2012). Stop-event-related potentials from intracranial electrodes reveal a key role of premotor and motor cortices in stopping ongoing movements. Frontiers in neuroengineering, 512. https://doi.org/10.3389/fneng.2012.00012
Mattia, M, et al. "Stop-event-related potentials from intracranial electrodes reveal a key role of premotor and motor cortices in stopping ongoing movements." Frontiers in neuroengineering vol. 5 (2012): 12. doi: https://doi.org/10.3389/fneng.2012.00012
Mattia M, Spadacenta S, Pavone L, Quarato P, Esposito V, Sparano A, Sebastiano F, Di Gennaro G, Morace R, Cantore G, Mirabella G. Stop-event-related potentials from intracranial electrodes reveal a key role of premotor and motor cortices in stopping ongoing movements. Front Neuroeng. 2012 Jun 29;5:12. doi: 10.3389/fneng.2012.00012. eCollection 2012. PMID: 22754525; PMCID: PMC3386527.
Copy Download .nbib Format: NLM
Multibaryons in Skyrme and quark models.

Physical review. D, Particles and fields

Gomm H, Lizzi F, Sparano G.
PMID: 9955537
Phys Rev D Part Fields. 1985 Jan 01;31(1):226-228. doi: 10.1103/physrevd.31.226.

No abstract available.

Cite
Gomm H, Lizzi F, Sparano G. Multibaryons in Skyrme and quark models. Phys Rev D Part Fields. 1985;31(1):226-228doi: 10.1103/physrevd.31.226.
Gomm, H., Lizzi, F., & Sparano, G. (1985). Multibaryons in Skyrme and quark models. Physical review. D, Particles and fields, 31(1), 226-228. https://doi.org/10.1103/physrevd.31.226
Gomm, et al. "Multibaryons in Skyrme and quark models." Physical review. D, Particles and fields vol. 31,1 (1985): 226-228. doi: https://doi.org/10.1103/physrevd.31.226
Gomm H, Lizzi F, Sparano G. Multibaryons in Skyrme and quark models. Phys Rev D Part Fields. 1985 Jan 01;31(1):226-228. doi: 10.1103/physrevd.31.226. PMID: 9955537.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 102 entries